Patent 7217689 was granted and assigned to Amgen on May, 2007 by the United States Patent and Trademark Office.
Erythropoietin analogs having at least one additional site for glycosylation, or a rearrangement of at least one site for glycosylation are disclosed. The invention also relates to DNA sequences encoding said erythropoietin analogs, and recombinant plasmids and host cells for analog expression.